We are live on ! Find out more
SIOX

Sio Gene Therapies Inc. Common Stock
SIOX

Delisted

SIOX was delisted on the 22nd of March, 2023.

Back to rankings

40 hedge funds and large institutions have $7.62M invested in Sio Gene Therapies Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% less funds holding

Funds holding: 41 → 40 (-1)

11% less capital invested

Capital invested by funds: $8.53M → $7.62M (-$904K)

18% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 11

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
40
Holders Change
-1
Holders Change %
-2.44%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
9
Reduced
11
Closed
4
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$5K

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$339K
2
SW
SVB Wealth
Massachusetts
+$32.3K
3
NM
Newtyn Management
New York
+$28.8K
4
Jane Street
Jane Street
New York
+$2.36K
5
TRCT
Tower Research Capital (TRC)
New York
+$1.13K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$88.4K
2
CIA
Cladis Investment Advisory
Montana
-$63.4K
3
Renaissance Technologies
Renaissance Technologies
New York
-$33.7K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$20K
5
UBS Group
UBS Group
Switzerland
-$17.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCMNY
1
Rubric Capital Management (New York)
New York
$1.96M +$339K +988,995 +16%
SCM
2
Suvretta Capital Management
New York
$1.66M – – –
TVWM
3
Tower View Wealth Management
Wisconsin
$1.35M -$3 -8 -0.1%
Vanguard Group
4
Vanguard Group
Pennsylvania
$516K -$88.4K -257,874 -12%
Hudson Bay Capital Management
5
Hudson Bay Capital Management
Connecticut
$471K – – –
NM
6
Newtyn Management
New York
$420K +$28.8K +84,141 +6%
PCA
7
Private Capital Advisors
Connecticut
$349K +$1.03K +3,013 New
CIA
8
Cladis Investment Advisory
Montana
$155K -$63.4K -185,000 -25%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$121K – – –
CC
10
Clearline Capital
New York
$110K – – –
BlackRock
11
BlackRock
New York
$109K +$2 +7 +0%
Renaissance Technologies
12
Renaissance Technologies
New York
$101K -$33.7K -98,394 -21%
State Street
13
State Street
Massachusetts
$49K – – –
ACM
14
ACT Capital Management
Pennsylvania
$41K – – –
BCM
15
Bridgeway Capital Management
Texas
$30K -$17.1K -50,000 -32%
Jane Street
16
Jane Street
New York
$28K +$2.36K +6,879 +7%
SW
17
SVB Wealth
Massachusetts
$26K +$32.3K +94,150 New
Northern Trust
18
Northern Trust
Illinois
$24K – – –
Two Sigma Investments
19
Two Sigma Investments
New York
$20K -$34 -100 -0.1%
Macquarie Group
20
Macquarie Group
Australia
$18K – – –
Franklin Resources
21
Franklin Resources
California
$16K – – –
MAM
22
Meeder Asset Management
Ohio
$16K +$48 +141 New
TRCT
23
Tower Research Capital (TRC)
New York
$11K +$1.13K +3,292 +9%
BFM
24
Boothbay Fund Management
New York
$8K – – –
Verition Fund Management
25
Verition Fund Management
Connecticut
$6K – – –
1
2

SIOX Hedge Fund Activity: Q3 2022 in Review

40 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q3 2022, worth a combined $7.62M — down 11% from $8.53M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of SIOX and 3 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 9 added.

The largest buyer was Rubric Capital Management (New York), adding an estimated $339K. The largest seller was Vanguard Group, cutting an estimated $88.4K.

  • 40 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q3 2022, down from 41 in Q2 2022.
  • Funds reported $7.62M of Sio Gene Therapies Inc. Common Stock stock for Q3 2022, down 11% quarter-over-quarter.
  • 3 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q3 2022 and 4 closed out, a net change of -1 holder.
  • The largest Sio Gene Therapies Inc. Common Stock buyer in Q3 2022 was Rubric Capital Management (New York), an estimated $339K added.
  • The largest Sio Gene Therapies Inc. Common Stock seller in Q3 2022 was Vanguard Group, an estimated $88.4K sold.

Based on aggregated 13F filings for Q3 2022.